NASDAQ:CALA

Calithera Biosciences Competitors

$2.05
-0.11 (-5.09 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.03
Now: $2.05
$2.15
50-Day Range
$2.15
MA: $2.56
$2.93
52-Week Range
$2.03
Now: $2.05
$7.42
Volume825,353 shs
Average Volume1.57 million shs
Market Capitalization$150.30 million
P/E RatioN/A
Dividend YieldN/A
Beta1.77

Competitors

Calithera Biosciences (NASDAQ:CALA) Vs. ANAB, IDYA, CLVS, SIGA, RLMD, and EVLO

Should you be buying CALA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Calithera Biosciences, including AnaptysBio (ANAB), IDEAYA Biosciences (IDYA), Clovis Oncology (CLVS), SIGA Technologies (SIGA), Relmada Therapeutics (RLMD), and Evelo Biosciences (EVLO).

AnaptysBio (NASDAQ:ANAB) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.

Profitability

This table compares AnaptysBio and Calithera Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AnaptysBioN/A-19.09%-17.94%
Calithera BiosciencesN/A-66.64%-56.60%

Institutional & Insider Ownership

74.0% of Calithera Biosciences shares are owned by institutional investors. 13.0% of AnaptysBio shares are owned by company insiders. Comparatively, 11.9% of Calithera Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

AnaptysBio has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.

Earnings and Valuation

This table compares AnaptysBio and Calithera Biosciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AnaptysBio$8 million74.95$-97,340,000.00($3.60)-6.09
Calithera Biosciences$22.25 million6.76$-89,860,000.00($1.90)-1.08

Calithera Biosciences has higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Calithera Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for AnaptysBio and Calithera Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AnaptysBio13302.29
Calithera Biosciences01302.75

AnaptysBio presently has a consensus price target of $30.2857, suggesting a potential upside of 38.23%. Calithera Biosciences has a consensus price target of $5.20, suggesting a potential upside of 153.66%. Given Calithera Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Calithera Biosciences is more favorable than AnaptysBio.

Summary

Calithera Biosciences beats AnaptysBio on 8 of the 12 factors compared between the two stocks.

IDEAYA Biosciences (NASDAQ:IDYA) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Valuation and Earnings

This table compares IDEAYA Biosciences and Calithera Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IDEAYA BiosciencesN/AN/A$-41,970,000.00($3.36)-5.52
Calithera Biosciences$22.25 million6.76$-89,860,000.00($1.90)-1.08

IDEAYA Biosciences has higher earnings, but lower revenue than Calithera Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Calithera Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IDEAYA Biosciences and Calithera Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IDEAYA BiosciencesN/A-28.83%-22.92%
Calithera BiosciencesN/A-66.64%-56.60%

Volatility & Risk

IDEAYA Biosciences has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for IDEAYA Biosciences and Calithera Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IDEAYA Biosciences00603.00
Calithera Biosciences01302.75

IDEAYA Biosciences presently has a consensus price target of $31.4444, indicating a potential upside of 69.42%. Calithera Biosciences has a consensus price target of $5.20, indicating a potential upside of 153.66%. Given Calithera Biosciences' higher possible upside, analysts plainly believe Calithera Biosciences is more favorable than IDEAYA Biosciences.

Insider and Institutional Ownership

62.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 74.0% of Calithera Biosciences shares are owned by institutional investors. 20.7% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 11.9% of Calithera Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

IDEAYA Biosciences beats Calithera Biosciences on 7 of the 12 factors compared between the two stocks.

Clovis Oncology (NASDAQ:CLVS) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Insider & Institutional Ownership

57.8% of Clovis Oncology shares are owned by institutional investors. Comparatively, 74.0% of Calithera Biosciences shares are owned by institutional investors. 6.6% of Clovis Oncology shares are owned by insiders. Comparatively, 11.9% of Calithera Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Clovis Oncology and Calithera Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Clovis Oncology-230.34%N/A-57.56%
Calithera BiosciencesN/A-66.64%-56.60%

Volatility & Risk

Clovis Oncology has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Clovis Oncology and Calithera Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Clovis Oncology12102.00
Calithera Biosciences01302.75

Clovis Oncology presently has a consensus price target of $7.00, indicating a potential upside of 23.46%. Calithera Biosciences has a consensus price target of $5.20, indicating a potential upside of 153.66%. Given Calithera Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Calithera Biosciences is more favorable than Clovis Oncology.

Earnings & Valuation

This table compares Clovis Oncology and Calithera Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clovis Oncology$143.01 million4.14$-400,420,000.00($7.60)-0.75
Calithera Biosciences$22.25 million6.76$-89,860,000.00($1.90)-1.08

Calithera Biosciences has lower revenue, but higher earnings than Clovis Oncology. Calithera Biosciences is trading at a lower price-to-earnings ratio than Clovis Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Calithera Biosciences beats Clovis Oncology on 10 of the 14 factors compared between the two stocks.

SIGA Technologies (NASDAQ:SIGA) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Insider & Institutional Ownership

29.3% of SIGA Technologies shares are held by institutional investors. Comparatively, 74.0% of Calithera Biosciences shares are held by institutional investors. 3.9% of SIGA Technologies shares are held by insiders. Comparatively, 11.9% of Calithera Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for SIGA Technologies and Calithera Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SIGA Technologies0000N/A
Calithera Biosciences01302.75

Calithera Biosciences has a consensus target price of $5.20, suggesting a potential upside of 153.66%. Given Calithera Biosciences' higher probable upside, analysts plainly believe Calithera Biosciences is more favorable than SIGA Technologies.

Valuation and Earnings

This table compares SIGA Technologies and Calithera Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SIGA Technologies$26.74 million21.74$-7,240,000.00N/AN/A
Calithera Biosciences$22.25 million6.76$-89,860,000.00($1.90)-1.08

SIGA Technologies has higher revenue and earnings than Calithera Biosciences.

Profitability

This table compares SIGA Technologies and Calithera Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SIGA Technologies34.62%37.31%25.33%
Calithera BiosciencesN/A-66.64%-56.60%

Risk & Volatility

SIGA Technologies has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.

Summary

SIGA Technologies beats Calithera Biosciences on 7 of the 12 factors compared between the two stocks.

Relmada Therapeutics (NASDAQ:RLMD) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Valuation and Earnings

This table compares Relmada Therapeutics and Calithera Biosciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relmada TherapeuticsN/AN/AN/A($2.16)-16.05
Calithera Biosciences$22.25 million6.76$-89,860,000.00($1.90)-1.08

Relmada Therapeutics has higher earnings, but lower revenue than Calithera Biosciences. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Calithera Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Relmada Therapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500.

Profitability

This table compares Relmada Therapeutics and Calithera Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Relmada TherapeuticsN/A-32.03%-31.41%
Calithera BiosciencesN/A-66.64%-56.60%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Relmada Therapeutics and Calithera Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Relmada Therapeutics01202.67
Calithera Biosciences01302.75

Relmada Therapeutics presently has a consensus price target of $63.3333, indicating a potential upside of 82.67%. Calithera Biosciences has a consensus price target of $5.20, indicating a potential upside of 153.66%. Given Calithera Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Calithera Biosciences is more favorable than Relmada Therapeutics.

Institutional & Insider Ownership

64.3% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 74.0% of Calithera Biosciences shares are owned by institutional investors. 9.3% of Relmada Therapeutics shares are owned by insiders. Comparatively, 11.9% of Calithera Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Calithera Biosciences beats Relmada Therapeutics on 9 of the 11 factors compared between the two stocks.

Evelo Biosciences (NASDAQ:EVLO) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.

Valuation and Earnings

This table compares Evelo Biosciences and Calithera Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A$-85,470,000.00($2.67)-4.06
Calithera Biosciences$22.25 million6.76$-89,860,000.00($1.90)-1.08

Evelo Biosciences has higher earnings, but lower revenue than Calithera Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than Calithera Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Evelo Biosciences and Calithera Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evelo BiosciencesN/A-159.17%-88.81%
Calithera BiosciencesN/A-66.64%-56.60%

Institutional and Insider Ownership

84.6% of Evelo Biosciences shares are held by institutional investors. Comparatively, 74.0% of Calithera Biosciences shares are held by institutional investors. 7.3% of Evelo Biosciences shares are held by company insiders. Comparatively, 11.9% of Calithera Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Evelo Biosciences has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Evelo Biosciences and Calithera Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evelo Biosciences02302.60
Calithera Biosciences01302.75

Evelo Biosciences currently has a consensus target price of $20.00, indicating a potential upside of 84.50%. Calithera Biosciences has a consensus target price of $5.20, indicating a potential upside of 153.66%. Given Calithera Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Calithera Biosciences is more favorable than Evelo Biosciences.

Summary

Calithera Biosciences beats Evelo Biosciences on 9 of the 11 factors compared between the two stocks.


Calithera Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AnaptysBio logo
ANAB
AnaptysBio
1.5$21.91-0.7%$599.59 million$8 million-8.08
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$18.56-1.0%$598.75 millionN/A-9.87Analyst Report
Clovis Oncology logo
CLVS
Clovis Oncology
1.2$5.67-1.9%$592.69 million$143.01 million-1.08
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$7.58-5.3%$581.37 million$26.74 million18.94
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$34.67-0.5%$580.62 millionN/A-16.05
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$10.84-6.5%$578.15 millionN/A-4.35Analyst Upgrade
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$23.61-2.1%$573.91 million$12.69 million-11.35News Coverage
Gap Up
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.0$42.87-0.6%$566.61 million$195.89 million122.49
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$16.55-2.3%$546.63 million$1.19 million-6.90
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$17.86-0.6%$543.69 millionN/A-5.19
OrganiGram logo
OGI
OrganiGram
1.6$2.34-11.1%$543.51 million$64.61 million-3.44Analyst Report
Decrease in Short Interest
Gap Down
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24-0.0%$531.75 millionN/A-3.15
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.84-1.0%$526.59 millionN/A-4.63
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.4$11.02-1.1%$523.94 millionN/A-8.54
89bio logo
ETNB
89bio
1.6$25.81-1.9%$517.10 millionN/A-5.11Insider Selling
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.96-4.5%$515.68 million$57.49 million-6.69
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$10.61-1.0%$515.18 millionN/A-5.44Analyst Upgrade
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$20.64-3.0%$513.23 millionN/A-8.13
Inventiva logo
IVA
Inventiva
0.0$13.27-0.9%$512.62 millionN/A0.00
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$12.04-0.2%$509.61 million$25 million-18.52
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$13.85-1.2%$507.37 millionN/A-3.99
Akouos logo
AKUS
Akouos
1.6$14.60-2.4%$502.27 millionN/A0.00
Provention Bio logo
PRVB
Provention Bio
1.6$7.81-3.1%$494.96 millionN/A-5.24Analyst Report
Increase in Short Interest
XBiotech logo
XBIT
XBiotech
1.0$16.48-1.7%$485.48 millionN/A1.14News Coverage
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.50-1.9%$484.34 million$58.12 million-15.70Gap Up
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.18-3.5%$478.24 million$59.22 million40.90
AC Immune logo
ACIU
AC Immune
1.3$6.51-0.0%$468.31 million$111.75 million-7.23Analyst Upgrade
Analyst Revision
Verastem logo
VSTM
Verastem
1.3$2.71-0.4%$465.22 million$17.46 million-1.92
Evolus logo
EOLS
Evolus
1.5$10.55-0.7%$461.38 million$34.92 million-5.20
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.17-0.9%$460.03 million$49.65 million-1.65
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.39-1.8%$455.79 million$102.31 million6.55Increase in Short Interest
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$33.20-7.7%$448.50 million$40,000.00-1.44Upcoming Earnings
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$5.81-1.7%$448.40 millionN/A-11.86
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.91-0.7%$447.35 million$109.33 million-2.14
Molecular Templates logo
MTEM
Molecular Templates
2.0$7.96-4.1%$446.17 million$22.27 million-3.90Analyst Revision
Geron logo
GERN
Geron
1.4$1.40-0.0%$445.94 million$460,000.00-4.00Decrease in Short Interest
Verona Pharma logo
VRNA
Verona Pharma
1.7$7.58-2.1%$439.15 millionN/A-2.30News Coverage
Altimmune logo
ALT
Altimmune
1.9$11.81-0.3%$438.74 million$5.80 million-5.93
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$2.83-0.7%$434.41 million$335 million-0.96
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.01-0.9%$431.48 million$6.07 million-3.35News Coverage
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.6$8.61-1.7%$429.85 million$72.96 million-2.79Analyst Report
News Coverage
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$16.51-0.4%$429.41 millionN/A-3.47
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.15-0.0%$427.02 million$56.50 million0.00
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$18.07-0.4%$423.99 millionN/A0.00
BCEL
Atreca
1.7$11.41-0.4%$420.24 millionN/A-4.05
MedAvail logo
MDVL
MedAvail
1.9$12.89-4.1%$411.71 million$1.03 million-3.16
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$3.66-4.1%$411.29 million$6.68 million-4.41News Coverage
ANI Pharmaceuticals logo
ANIP
ANI Pharmaceuticals
1.9$33.01-3.1%$408.17 million$206.55 million-16.59
Seelos Therapeutics logo
SEEL
Seelos Therapeutics
1.3$5.10-2.0%$399.24 million$380,000.000.00
XOMA logo
XOMA
XOMA
1.5$35.44-1.6%$398.98 million$18.37 million-31.93Increase in Short Interest
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.